Distribution agreement with Ravenswood for SlimBiome®
RNS & Investor News
LPLDL® license agreement for new application in hypertension
20 May 2019
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a license agreement with Nutrilinea Srl. ("Nutrilinea") for the use of LPLDL® in a food supplement for the reduction of high blood pressure (hypertension). Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe.
Nutrilinea, based near Milan in northern Italy, is a manufacturer of food supplement formulations containing probiotics, with over 15 years' experience in the development of products for the food and pharmaceutical industries in Europe and the United States. It is one of OptiBiotix's preferred manufacturers, and currently produces the Company's CholBiome®, CholBiome®x3 and SlimBiome® Medical products. Nutrilinea has technology that enables the production of multilayer tablets used in CholBiome®x3 which will also be used for this new product. In an independent human study by the University of Reading, there was a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LPLDL® compared to a control group (Costabile et al., 2017). The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to "dramatically reduce" a person's lifetime risk of cardiovascular disease.
Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms have lead doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 million in the US.
Dr Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are delighted to announce this deal with Nutrilinea who are covering the cost of product development, manufacturing and human studies, for a food supplement to reduce blood pressure. This broadens the use of LPLDL® beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. Hypertension is a global health issue which is on the rise where there are very few active ingredients or supplements proven to lower blood pressure in humans. The development of a hypertension product containing LPLDL® has the potential to address a large global market of unmet clinical need."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)|
|Liam Murray / Jo Turner||Tel: 020 7213 0880|
|Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023